Daniel P. Flaherty
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
Publications
112
Citations
1,633
Est. group size
~15
Recurring co-author estimate
Active years
20
Publishing since 2007
Daniel P. Flaherty's research focuses on developing small-molecule drugs, particularly enzyme inhibitors, to combat drug-resistant bacterial infections such as gonorrhea and vancomycin-resistant enterococci, with carbonic anhydrase (an enzyme involved in regulating acidity in cells) as a frequent drug target. The lab also works on related biochemical targets including deubiquitinating enzymes (proteins that remove regulatory tags from other proteins) and adenylyl cyclase for non-opioid pain treatment, using medicinal chemistry and structure-activity studies to design and optimize new compounds.
Publication output has grown substantially over the last decade, rising from a handful of papers per year in 2017-2019 to a sustained higher rate of roughly 8-14 papers annually from 2021 onward.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- MassIVE MSV000100717 - structure activtiy relationsip studies for 134thiadiazole based bacterial carbonic anhydrase inhibitors with invivo efficacy against drug resistant gonorrhoeae
California Digital Library · 2026
- Substrate biasing in UCHL5 proteoforms
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Redesigning oxazolidinones as carbonic anhydrase inhibitors against vancomycin-resistant enterococci
European Journal of Medicinal Chemistry · 2025
- First reported case of a spontaneous and healthy pregnancy in a woman with persistent CAR T-cells 5 years after treatment for diffuse large B-cell lymphoma
Journal for ImmunoTherapy of Cancer · 2025
- Targeting Adenylyl Cyclase 1 for Development of Non-Opioid Pain Therapeutics (Abstract ID: 166855)
Journal of Pharmacology and Experimental Therapeutics · 2025
- MPN-1046: Myelofibrosis in Real-World Practice: Mutation Impact and Treatment Strategies
Clinical Lymphoma Myeloma & Leukemia · 2025
- Development of Penicillin-Based Carbonic Anhydrase Inhibitors Targeting Multidrug-Resistant <i>Neisseria gonorrhoeae</i>
Journal of Medicinal Chemistry · 2024
- Optimization of Ethoxzolamide Analogs with Improved Pharmacokinetic Properties for <i>In Vivo</i> Efficacy against <i>Neisseria gonorrhoeae</i>
Journal of Medicinal Chemistry · 2024
- Unguarded liabilities: Borrelia burgdorferi’s complex amino acid dependence exposes unique avenues of inhibition
Frontiers in Antibiotics · 2024
- Neisseria gonorrhoeae carbonic anhydrase inhibition
The Enzymes · 2024
- Enterococci carbonic anhydrase inhibition
The Enzymes · 2024
- Targeting Adenylyl Cyclase 1 for Development of Non-Opioid Pain Therapeutics
Journal of Pharmacology and Experimental Therapeutics · 2024
- Re-evaluating the Need for Visual Signals in Unsupervised Grammar Induction
2024
- Mechanism-based inhibition of gut microbial tryptophanases reduces serum indoxyl sulfate
Cell chemical biology · 2023
- Carbonic Anhydrase Inhibition as a Target for Antibiotic Synergy in Enterococci
Microbiology Spectrum · 2023
- Journal of Medicinal Chemistry×8
- Journal of Enzyme Inhibition and Medicinal Chemistry×7
- bioRxiv (Cold Spring Harbor Laboratory)×4
- Antibiotics×3
- ACS Infectious Diseases×2
- Katrina J. Holly
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Chad S. Hewitt
Chemistry · Purdue University West Lafayette
- Karson S. Putt
Computer Science · Purdue University West Lafayette
- Steven J. Metallo
Biochemistry, Genetics and Molecular Biology · Indiana University
- Weiwei An
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile